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Abstract
Background: Aluminium-containing phosphate binders have long been used for treatment of hyperphosphatemia
in dialysis patients. Their safety became controversial in the early 1980’s after reports of aluminium related
neurological and bone disease began to appear. Available historical evidence however, suggests that neurological
toxicity may have primarily been caused by excessive exposure to aluminium in dialysis fluid, rather than
aluminium-containing oral phosphate binders. Limited evidence suggests that aluminium bone disease may also
be on the decline in the era of aluminium removal from dialysis fluid, even with continued use of aluminium
binders.
Discussion: The K/DOQI and KDIGO guidelines both suggest avoiding aluminium-containing binders. These
guidelines will tend to promote the use of the newer, more expensive binders (lanthanum, sevelamer), which have
limited evidence for benefit and, like aluminium, limited long-term safety data. Treating hyperphosphatemia in
dialysis patients continues to represent a major challenge, and there is a large body of evidence linking serum
phosphate concentrations with mortality. Most nephrologists agree that phosphate binders have the potential to
meaningfully reduce mortality in dialysis patients. Aluminium is one of the cheapest, most effective and well
tolerated of the class, however there are no prospective or randomised trials examining the efficacy and safety of
aluminium as a binder. Aluminium continues to be used as a binder in Australia as well as some other countries,
despite concern about the potential for toxicity. There are some data from selected case series that aluminium bone
disease may be declining in the era of reduced aluminium content in dialysis fluid, due to rigorous water testing.
Summary: This paper seeks to revisit the contemporary evidence for the safety record of aluminium-containing
binders in dialysis patients. It puts their use into the context of the newer, more expensive binders and increasing
concerns about the risks of calcium binders, which continue to be widely used. The paper seeks to answer
whether the continued use of aluminium is justifiable in the absence of prospective data establishing its safety,
and we call for prospective trials to be conducted comparing the available binders both in terms of efficacy and
safety.
Background
Oral phosphate binding agents have been used for the
treatment of hyperphosphatemia in dialysis patients for
decades. Their safety record was marred in the early
1980’s by reports of aluminium-related neurological and
bone disease, and so-called “dialysis dementia” led to
limitations or complete avoidance of their use and a
search for alternative agents. Initially the neurological
syndrome was attributed to orally administered alumi-
nium, but historical evidence suggests that severe toxi-
city may have primarily been caused by excessive
exposure to aluminium in dialysis fluid, rather than alu-
minium-containing oral phosphate binders. There were
reports of epidemics of dementia in specific dialysis cen-
tres were the aluminium content of the water used for
dialysis was later found to be very high, suggesting that
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water. With the advent of stringent testing of dialysis
water for aluminium and other minerals and their
removal by reverse-osmosis, it became possible to
remove aluminium almost completely from dialysis
water. Since then “dialysis dementia” has completely dis-
appeared, even in countries where aluminium continues
to be used as a binder. A small body of evidence sug-
gests that aluminium bone disease may also be on the
decline in the era of aluminium removal from dialysis
fluid, even with continued use of aluminium binders.
Contemporary guidelines for the treatment of hyperpho-
sphatemia in dialysis patients continue to recommend
avoidance or restriction of aluminium binders due to
the concerns of potential neurological toxicity and advo-
cate the use of newer, more expensive binders whose
long term safety remains unclear. Prospective rando-
mised trials of the different agents for phosphate bind-
ing to establish both their safety and efficacy in terms of
hard clinical endpoints are lacking, and should be pur-
sued by the nephrology community.
Discussion
1. Historical evidence suggests that water, not binders,
was the source of previous cases of aluminium toxicity in
dialysis patients
The problem of phosphate accumulation became appar-
ent quite early in the history of dialysis. Soft tissue and
vascular calcification could often be clearly visualised on
plain x-ray because of calcium phosphate deposition in
the vessel walls. As phosphate is present in most foods,
dietary restriction of phosphate was not an adequate
solution. The treatment of hyperphosphatemia was
intensified by the additional mealtime administration of
phosphate binders, such as aluminium hydroxide and
calcium carbonate. Phosphate accumulation was also
identified early as an important cause of secondary
hyperparathyroidism. Slatopolsky demonstrated in dogs
with surgically induced renal failure that hyperparathyr-
oidism was universal, but could be prevented by dietary
phosphate restriction [1] or by adding aluminium salts
to their food [2] to bind the phosphate and thereby pre-
vent its absorption. By 1970 the administration of alumi-
nium hydroxide and/or calcium carbonate as phosphate
binders in dialysis patients was virtually universal
practice.
In 1972, Alfrey was one of the first to report that dia-
lysis patients in his unit in Denver, Colorado, frequently
died within a few years due to the development of a
severe encephalopathy characterised by seizures, stutter-
ing dysarthria and a distinctive wave and spike pattern
on EEG. The term, “dialysis dementia,” was coined and
Alfrey subsequently demonstrated that all dialysis
patients accumulated more aluminium in their tissues
than controls with normal renal function and that this
accumulation was particularly marked in patients dying
of dialysis dementia. He correctly stated that the cause
of dialysis dementia was the accumulation of aluminium
in the grey matter of the brain [3].
Although aluminium hydroxide phosphate binders
were suggested to be the source of this aluminium toxi-
city, the hypothesis did not explain that while the use of
aluminium to bind phosphate was almost universal, the
problem of dialysis dementia appeared to be confined,
at least initially, to Alfrey’s unit. This may have been
due to his acute awareness of the toxicity of phos-
phorus, and more aggressive treatment with aluminium
binders, or it may have been due to the aluminium toxi-
city not coming from binders. An eloquent study by
Candy et al cast further doubt for some on the theory
of the aluminium accumulation being due to binders.
This post-mortem study showed that the administration
of oral aluminium in a dosage of several grams daily led
to the absorption of only microgram quantities of alumi-
nium. The frontal cortex in the brains of dialysis
patients exposed to aluminium-based phosphate binders
had a mean aluminium content of just 1.2 to 14.1 μg/g
dry weight, despite serum levels of aluminium between
5a n d4 9 . 9μg/L [4]. Only half of the patients studied
had higher brain aluminium content than control
patients. In terms of the elevation of serum levels gener-
ated by oral aluminium ingestion and its effect of serum
phosphate, one study of 41 patients on haemodialysis
revealed that 0.9 grams of aluminium daily reduced the
phosphate from 2.10 to 1.48 mmol/L and caused the
serum aluminium to rise from 6.8 to 13.8 μg/L (0.25 to
0.51 μmol/L) [5]. In our hospital serum aluminium
levels in patients taking oral aluminium are less than 40
μg per litre (< 1.5 μmol/L) in 98% of samples, consistent
with reported rates from elsewhere in the world. The
direct quantification of absorption of aluminium is diffi-
cult in humans due to the lack of stable isotopes able to
be measured.
In contrast, evidence emerged that exposure to alumi-
nium in dialysate was far more likely to promote alumi-
nium toxicity than oral exposure. Aluminium crosses
the dialysis membrane readily and is 80% plasma protein
bound, such that it continues to dialyse into the patient
until the plasma aluminium concentration is approxi-
mately four times the dialysate concentration [6]. In
1979 a study was published in the UK involving 18 dia-
lysis centres [7] in which the concentration of alumi-
nium in the water used to make dialysate was measured
at each centre and correlated with the incidence of dia-
lysis encephalopathy and fracturing osteodystrophy.
Those units with the highest concentration of alumi-
nium in the water were also the units with the highest
incidence of aluminium toxicity.
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used to prepare dialysis fluid and dialysis dementia
came from Eindhoven in Holland [8], Six patients dia-
lysing at one centre in that town developed dialysis
dementia. The dialysate was prepared by adding water
to the dialysate salts. Part of the water was ordinary tap
water while part was obtained from the hospital boiler.
The two were mixed to provide an ultimate temperature
in the dialysate tank of 40°C. The hospital boiler con-
tained two aluminium anodes as a protection against
corrosion. A 3 amp current passed between these
anodes and the boiler wall. Over a two year period, the
aluminium anodes (which weighed 32 kg) disintegrated
completely. They ended up as aluminium hydroxide on
the bottom of the hospital boiler. As a result of this, the
aluminium content of the dialysis fluid was extremely
high. In a second dialysis unit in Eindhoven, dialysate
preparation was similar, but there were no aluminium
anodes in the boiler and no cases of dialysis dementia
occurred.
An outbreak of aluminium toxicity subsequently
occurred in Edinburgh in 1978/79 [9] whereby 12
patients developed microcytic anaemia despite normal
iron stores. Seven patients developed fracturing osteody-
strophy and 1 developed dialysis dementia. The serum
aluminium levels in the 12 patients with microcytic
anaemia ranged from 7 to 22 μmol/L, whilst the water
used to prepare the dialysate had a measured aluminium
content which ranged from 0.8 μmol/L to 9.8 μmol/L
and was thus identified as the source of aluminium toxi-
city. A reverse osmosis unit was installed to remove all
aluminium from the water. After 15 months of dialysis
against aluminium-free dialysate, there was a marked
improvement in both serum aluminium levels and
microcytic anaemia.
By the 1980s it became clear that the most important
cause of epidemic aluminium toxicity was contamina-
tion of the water used to make dialysate. Robson et al
[10] reported improvement in four patients with alumi-
nium-related bone disease following dialysis against alu-
minium-free dialysate, with stabilisation of a further
three cases. No new cases of aluminium-related bone
disease occurred after the introduction of reverse osmo-
sis treatment of the water supply, which eliminated alu-
minium contamination.
There are very limited data to examine the relative
contributions of oral and dialysate aluminium to toxicity
over time, particularly in the era of more rigorous
removal of aluminium from dialysis water. One impor-
tant study from the late 1990’s does shed some light on
this, however. Mazzaferro et al [11] examined blood and
bone aluminium levels over three time periods - 1984 to
1987, 1998 to 1991 and 1992 to 1995, in 105 haemodia-
lysis patients in Italy. In the last time period the
aluminium content of the dialysate was controlled by
reverse osmosis and was under 10 μg per litre. The
average aluminium content in bone halved between the
first and last periods and aluminium-related bone dis-
ease did not occur after 1992 in spite of the continued
used of oral aluminium hydroxide to bind phosphate, at
doses of 2.6 ± 2.2 g/day. Whilst this paper can not
prove the safety of oral aluminium, it is consistent with
the theory that aluminium in dialysis water is a stronger
risk factor for aluminium accumulation than oral alumi-
nium binders.
While sporadic cases of aluminium toxicity may have
been due to the administration of aluminium as a phos-
phate binder, it is clear that epidemics of aluminium
toxicity were due to aluminium in the dialysis fluid.
Where toxicity occurs in patients not yet on dialysis, the
dialysis fluid obviously cannot be blamed. Such cases
have occurred, but they have been limited to children
and to CKD patients taking citrate in addition to
aluminium.
Children seem to absorb aluminium more readily than
adults and there are several reports of children with
renal failure developing aluminium toxicity from alumi-
nium-containing phosphate binders prior to commen-
cing dialysis [12]. Infants given aluminium-containing
antacids showed significant aluminium absorption com-
pared to controls, as shown by blood and urine alumi-
nium levels [13]. Furthermore, a case series of three
infants who were not yet on dialysis, but treated with
aluminium developed osteomalacia and accumulation of
a l u m i n i u mi nb o n eo nb o n eb i o p s y[ 1 4 ] .P l a s m aa l u m i -
nium levels in these infants averaged 6.6 μmol/L. This
paper, published in the New UK Journal of Medicine,
was probably one of the most influential in warning that
aluminium should therefore be avoided in young chil-
dren, or at least given with extreme caution.
Citrate was found to increase aluminium absorption
from the gut. In the mid-1980’s, Bakir et al [15]
reported the development of dialysis dementia in four
patients who had been treated concurrently with oral
aluminium and Shohl’s solution, a combination of citric
acid and sodium citrate. Two of these patients were not
yet on dialysis. All four patients had very high serum
aluminium levels and all four died. A similar report
from elsewhere in the USA [16] detailed a series of
eight patients who died within a 6-month period from a
syndrome similar to dialysis dementia. They had been
receiving aluminium hydroxide concurrently with a
citrate solution used to control metabolic acidosis. Post-
mortem serum aluminium levels were markedly elevated
in two of the patients. Consequently, aluminium levels
were measured routinely in that same unit thereafter
and the only dialysis patients found to have high levels
a f t e rt h a tt i m ew e r et h o s eo nS h o h l ’ss o l u t i o ni n
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ders, or four other patients receiving deferoxamine as
therapy for aluminium overload. Three female patients
with alterations in mental state after this time had rever-
sal of their symptoms with cessation of the Shohl’s solu-
tion and aluminium.
In studies in the rat, Froment et al [17] showed that
the co-administration of citrate and aluminium
increased urinary aluminium excretion 50-fold com-
pared with the administration of aluminium alone. The
reason for this is that aluminium citrate is much more
soluble at physiological pH than either aluminium
hydroxide or aluminium chloride. Further studies in
humans identified that the high solubility of aluminium
citrate enhanced gastrointestinal absorption of alumi-
nium in the presence of citrate, and was responsible for
the markedly elevated levels of aluminium and conse-
quent neurological symptomatology seen in patients tak-
ing citrate supplements. Alfrey, Froment and others [18]
were also able to demonstrate a reduction in aluminium
levels after withdrawal of citrate, despite continuation of
aluminium binders as the final evidence of this interac-
tion being the cause of the syndrome. Shortly after-
wards, citrate ceased to be used as treatment for uremic
acidosis and bicarbonate was used instead.
There remain no reported cases of neurological toxi-
city due to aluminium binders in the absence of conco-
mitant use of citrate in adult pre-dialysis CKD patients
in the literature, and importantly, no reports of
aluminium toxicity associated with low blood levels of
aluminium (<1.5 μmol/L). It is possible therefore, that a
threshold of aluminium in the blood such as this level
could be chosen and tested prospectively as a safety
end-point.
2. Contemporary use of aluminium-based binders in the
era of greatly improved water quality has not been
associated with epidemics of aluminium toxicity
Aluminium-based phosphate binders have continued to
be used not only in Australia but elsewhere in the
world, albeit less commonly in Europe and very little in
North America. The Dialysis Outcomes and Practice
Patterns Survey (DOPPS) reports on aluminium usage,
and as recently as the third survey (2007) found sub-
stantial usage of aluminium binders in Germany, Italy
and Spain, as well as in Australia (Figure 1).
We continue to use aluminium, but principally as a
second-line agent after calcium carbonate. At any given
time, there would be approximately 200 dialysis patients
taking aluminium hydroxide. However, in spite of con-
stant vigilance for clinical and laboratory manifestations
of aluminium overload, the last identified case of alumi-
nium toxicity occurred 25 years ago in a patient with
dialysis dementia who had serum aluminium levels
between 2 and 3 μmol/L and had dialysed at home
against a dialysate containing a measured aluminium
level of 1 μmol/L. A similar experience had been
observed in Edinburgh where the majority of patients
Figure 1 Aluminium binder use by country in DOPPS 3, 2007. (source: http://www.dopps.org/annualreport/html/pb_aub_c_mostrec2009.
htm)
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excess of 6 μmol/L.
Serum aluminium concentrations are monitored every
3 months in our unit and aluminium hydroxide is dis-
continued when the serum level is over 1.5 μmol/L.
This level is currently encountered in less than 2% of
our dialysis population. These findings are in keeping
with contemporary data from the US, whereby elevated
aluminium levels were identified in 2.1% and 2.5% of
large cohorts of hemodialysis patients tested in 2000
and 2003, respectively [19]. That study also noted that
the frequency of detection of elevated aluminium levels
was actually on the decline, possibly related to better
water treatment. A UK study of aluminium testing in
dialysis patients queried whether such testing was super-
fluous, [20] although the dialysis patients in that study
were not taking any alumini u m - b a s e db i n d e r sa n di n
that situation aluminium testing of the dialysis water
supply only could be argued to be an acceptable mini-
mum safety requirement. On the other hand, given the
rare possibility of alternative means of heightened diet-
ary aluminium exposure, such as with inadvertent citrate
consumption, continuing to test aluminium levels could
be seen to be a safer strategy. An unanswered question
is whether an increase in serum aluminium levels over
time indicates tissue accumulation of aluminium, and if
so, at what serum aluminium level therapy should be
withdrawn. This is a question for which there are no
published data. Single measurements of serum alumi-
nium do show correlation with aluminium bone disease
(ABD) with one study showing a 3-fold higher risk for
ABD in those patients in the highest quartile of serum
aluminium [21]. However in that study, there was no
threshold level of aluminium which discriminated
between those patients with ABD and those without.
There is however not a single case in the literature of
significant aluminium toxicity occurring in the presence
of serum aluminium levels of less than 1.5 μmol/L, so it
is possible that this level of aluminium could be a start-
ing point for a safety threshold.
In terms of aluminium-related bone disease, this entity
is no longer clinically observed at our unit either.
Although bone biopsies are not routinely undertaken in
all hemodialysis patients, we have, as part of a research
project into bone histology in patients converting to
alternate nightly haemodialysis, performed bone biopsies
in a cohort of 26 patients [22]. The majority of these
individuals had normal or increased bone turnover but
none had signs of aluminium accumulation, despite the
majority having been on long-term aluminium-based
binder therapy at some stage prior to the study. The
only other contemporary data published on the contin-
ued use of aluminium binders in the era of ultra pure
water was the aforementioned Spanish study [5] which
looked at a cohort of hemodialysis patients continuing
to take aluminium-based binders but with monitoring of
serum and water aluminium levels from 2005 to 2007.
In that investigation, around one in six patients were
taking aluminium hydroxide (233 mg tablets) for a
mean duration of 17 months, at a mean dose of 3.9 ±
2.3 tablets/day. The serum aluminium levels rose from
6.8 to 13.8 μg/L on average, with no patients exceeding
the 40 μg/L safety threshold or developing evidence of
toxicity, such as microcytosis or anaemia. This level is
similar to the 1.5 μmol/L level discussed previously.
3. Aluminium-based binders are effective and cheap
Aluminium remains an effective phosphate binder, and
may be safe in an adult dialysis population provided
blood levels are carefully and regularly monitored and
the agent is withdrawn if these levels rise. Used as a
phosphate binder, aluminium will usually reduce serum
phosphate by approximately 0.3 mmol/L. A reduction of
this amount may equate to a mortality reduction of 10
to 15%, if the data on attributable risk to hyperphospha-
temia [23] are accurate. Looking at this another way,
failure to use this effective phosphate binding agent
could be costing one or two lives per year in the aver-
age-sized dialysis unit.
In terms of phosphate targets, the K/DOQI guidelines
[24] recommend that predialysis phosphate levels be run
at 1.13 to 1.78 mmol/L, even though they readily
acknowledge that such targets are difficult to achieve in
practice. For example, in the study by Cheng et al [25]
of 33 patients, 76% of whom received sevelamer in an
average dose of 7.7 grams daily, the mean serum phos-
phate concentration was 2.3 mmol/L. In our hospital,
the mean predialysis serum phosphate level in the hae-
modialysis population is 1.7 mmol/L. Some of our
patients are on haemodiafiltration, and our average dia-
lysis duration is 13.5 hours per week, both of which
would be expected to have a beneficial impact on phos-
phate control compared with centres which only per-
form short hours haemodialysis. However, despite the
use of oral aluminium hydroxide in addition to other
agents, we manage to achieve the K/DOQI phosphate
target of <1.75 mmol/L in only 55% of our dialysis
patients (unpublished data). With the less potent agents
such as calcium or sevelamer, we would be unlikely to
achieve as good a result without a greater pill burden.
This is consistent with the previously mentioned con-
temporary Spanish study of patients taking aluminium
binders, the proportion of patients with a serum phos-
phate levels <5 mg/dL (1.25 mmol/L) rose from 4.9% to
73.2% when aluminium was used in combination with
either sevelamer or calcium [5], reinforcing the effective-
ness of adjuvant therapy with aluminium hydroxide in
achieving serum phosphate targets.
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the use of aluminium-containing phosphate binders
altogether and only recommend their use as a short-
term therapy (≤4 weeks) in patients with serum phos-
phorus levels >7.0 mg/dL (2.26 mmol/L), and for one
course only, to be replaced thereafter by other phos-
phate binders [24]. Moreover, the K/DOQI guidelines
recommend that the “total dose of elemental calcium
provided by the calcium-based phosphate binders should
not exceed 1,500 mg/day (opinion), and the total intake
of elemental calcium (including dietary calcium) should
not exceed 2,000 mg/day (opinion).” If these guidelines
are followed, there is likely to be a substantial shift in
clinical practice away from the use of calcium- and alu-
minium-based phosphate binders to non-calcium-based
phosphate binders, such as sevelamer and lanthanum,
which are considerably more expensive. Manns et al
[26] estimated that compliance with the guidelines will
lead to 64% of dialysis patients in the USA (where alu-
minium is largely not used at all) being prescribed seve-
lamer, at a staggering additional cost of US$ 781 million
per annum. A subsequent economic evaluation of seve-
lamer in CKD patients considering 4 separate Markov
modelling strategies based on data obtained from the
DCOR study [27] found that the use of sevelamer was
associated with a cost per quality-adjusted life year
(QALY) gained that exceeded what would usually be
considered good value for money (CAN$105,000 - CAN
$278,100). The authors concluded that “this strategy
remains economically unattractive, particularly given the
uncertainty of clinical benefit in this group.” The exact
costs and benefits of the use of newer binders remain to
be seen, but it may take some years to realise their
potential benefits of cost-savings related to lower CKD-
MBD morbidity.
In terms of comparative studies of different phosphate
binders, there are several worthy of mention. One small
randomised controlled trial of aluminium hydroxide ver-
sus both calcium carbonate and calcium acetate [28],
concluded that “aluminium tended to be the most effec-
tive phosphate binder” and also noted that in most
patients taking either form of calcium, additional alumi-
nium was necessary to adequately control phosphate.
Over the 12 month duration of the study, there was no
difference in serum aluminium levels in patients who
were taking aluminium compared to those who were
not. This probably reflected improvements in water
treatment to remove aluminium, such as the use of dou-
ble reverse-osmosis units, which all but eliminate alumi-
nium from the water used to make dialysate. However,
other than serum aluminium levels, no other specific
safety criteria for the use of aluminium were analysed
(such as bone biopsies, fracture rates or neurological
events).
In peritoneal dialysis patients, one small, short-term
study of aluminium versus sevelamer [29] found no sig-
nificant difference between the two interventions in
terms of phosphate lowering or side effects, although
the phosphate levels were numerically (although not sta-
tistically significantly) lower in the patients taking alumi-
nium. Of note, there were only 15 patients in each
group of this cross-over study, so the numbers may
have been too small to reveal a true difference. Alumi-
nium levels were not measured in this study, despite
aluminium hydroxide doses as high as 5.7 g per day
being used.
Currently in Australia, the relative costs of aluminium
hydroxide versus sevelamer or lanthanum for a typical
daily dose are 72¢ per day versus $10.80 or $13.20 per
day, respectively. This is for typical doses of 2 tablets
taken three times per day with meals for aluminium or
sevelamer, or one 750 mg tablet of lanthanum three
times daily based on costs at our hospital pharmacy.
Over a year this represents costs of $262 per patient for
aluminium, and $3942 or $4818 for sevelamer and
lanthanum respectively, or a cost differential of between
$3680 and $4556 per patient per year. For a dialysis unit
with 100 patients this is clearly a very significant
expense.
Safety however is obviously a more important consid-
eration than cost. From the DOPPS Studies, it is clear
that many thousand dialysis patients have received alu-
minium as a phosphate binder over the last 15 to 20
years. Despite the strategy not being formally tested in a
prospective trial, there is not a single paper in the litera-
ture from this period describing significant aluminium
toxicity in an adult patient whose aluminium level was
regularly monitored and where the drug was discontin-
ued if the plasma level reached 1.5 μmol/L. This strategy
c o u l db eu s e da st h eb a s i sf o rtesting the safety of alu-
minium binders in a prospective trial.
Summary
In summary, the historical data which have raised con-
cern about neurological and bone toxicity of alumi-
nium-based phosphate binders may no longer be
relevant to contemporary practice. This is due largely to
the more rigorous treatment and testing of dialysis
water in most haemodialysis units, and also the regular
measurement of serum aluminium levels in dialysis
patients taking aluminium binders. However, due to the
difficulties in measuring aluminium accumulation in
humans directly, toxicity of aluminium remains a con-
cern. Serum aluminium levels in dialysis patients receiv-
ing aluminium binders are higher than in those not
receiving aluminium binders, suggesting some accumu-
lation, the toxicity of which has not been adequately
studied.
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toxicity are fortunately no longer seen in contemporary
haemodialysis practice, and less severe toxicities such as
anemia and aluminum-related bone disease appear to be
decreasing with time in centres where it is being looked
for. The relative contribution of aluminium binders to
aluminium toxicity would appear to be minor based on
the available evidence.
Newer phosphate binders, such as sevelamer and
lanthanum, are limited by both lack of evidence of bene-
fit in terms of hard clinical end-points (cardiovascular
disease, mortality) but also by lack of long-term safety
data. Lanthanum accumulation has been well documen-
ted in patients taking lanthanum carbonate [30,31],
although the long-term effects on patient safety are
uncertain. Likewise, such safety data for aluminium bin-
ders and even calcium binders are lacking. Indeed, there
are no head-to-head trials of different phosphate binders
comparing their safety, efficacy (especially with respect
to patient-level outcomes) and cost-effectiveness. Con-
temporary guidelines however, would tend to promote
t h en e w e r ,m o r ec o s t l ya g e n t s .T h eo n u si so nt h e
nephrology community to perform trials to establish
high level evidence relating to all aspects of manage-
ment of hyperphosphatemia including the benefits of
lowering serum phosphate per se, as well as questions
relating to specific agents and the associated health eco-
nomic considerations. Moreover large trials which are
adequately designed to answer these important ques-
tions, should consider all available phosphate binders,
including aluminium.
The utility of safety standards of routine water testing
for aluminium and monitoring of serum aluminium
levels for patients on oral aluminium-based phosphate
binders, as well as the avoidance of oral citrate in
patients taking aluminium, could reasonably be tested in
a prospective, randomised trial, and provides a tantalis-
ing opportunity for a potentially significant cost-saving
for dialysis patients if the safety of aluminium as a bin-
der could be established.
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